DAXXIFY™ is FDA-approved to help smooth moderate to severe lines between the brows. It is the only long-lasting frown line treatment powered by a peptide with results that last on average 6 months and up to 9 months for some. Produced by Revance Therapeutics, Daxxify is a revolutionary new product.

In short, no, and here’s why. Units are like fingerprints—they are a proprietary measurement of a treatment’s unique potency. Because of the differences in how treatments are formulated and tested, you cannot compare or convert Units between them, just like you cannot compare 2 fingerprints. A clearer way to understand dosing is to look at how many nanograms of active ingredient (botulinum toxin type A) a product has. Double the Units does not mean double the dose DAXXIFY™ Approved frown line dose: 40 Units Amount of active ingredient: 0.18 nanograms BOTOX® Cosmetic Approved frown line dose: 20 Units Amount of active ingredient: 0.18 nanograms DYSPORT® Approved frown line dose: 50 Units Amount of active ingredient: 0.27 nanograms As you can see, despite the number of Units, DAXXIFY™ isn’t 2x the dose of BOTOX® Cosmetic, nor is Dysport® 2.5x the dose of BOTOX® Cosmetic. Talk to your provider about DAXXIFY™ and your aesthetic goals.

DAXXIFY™ was studied in the largest-ever clinical study for a frown line treatment and included more than 2,800 people across different ages and skin types. Here are some things you should know about DAXXIFY™:

• There were no serious treatment-related side effects
• The active ingredient in DAXXIFY™ is botulinum toxin type A, an ingredient that has been used in frown line treatments for more than 20 years • 96% of people treated with DAXXIFY™ were satisfied with their results‡
• 96% of patients reported they were satisfied on a 7-point scale when evaluated at 4 weeks in clinical studies.
• The safety and efficacy of DAXXIFY™ is well established, with more than 20 years of research. In fact, DAXXIFY™ has been studied in the largest ever phase 3 clinical trial program conducted for a frown line treatment and included more than 2,400 people across different ages and with different skin types. There were no notable differences in how DAXXIFY™ performed in clinical trial patients with varying skin types.

All frown line treatments require a special ingredient to stabilize botulinum toxin A, the protein responsible for helping smooth moderate to severe frown lines. For instance, BOTOX® Cosmetic uses human serum albumin (HSA), a blood product, as its stabilizer. Dysport®, another frown line treatment, uses HSA as a stabilizer and cow’s milk protein as a protectant. DAXXIFY™ is unique because it is the only formulation that uses a novel peptide as a stabilizer and does not contain human or animal byproducts.

• DAXXIFY™ was studied in the largest-ever clinical study conducted for a frown line treatment and included more than 2,400 people across different ages and skin types.
  There were no serious treatment-related side effects in clinical trials for DAXXIFY™.
• The active ingredient in DAXXIFY™ is botulinum toxin type A, an ingredient that has been used in frown line treatments for more than 20 years. 96% of people treated with DAXXIFY™ were satisfied with their results.
• 96% of patients reported they were satisfied on a 7-point scale when evaluated at 4 weeks in clinical studies.